Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome).
about
Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancerPalmar-plantar erythrodysesthesia associated with chemotherapy and its treatmentSkin toxicity in a patient with ovarian cancer treated with pegylated liposomal doxorubicin: A case report and review of the literatureAccelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies.Multikinase Inhibitor-Induced Hand-Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management.Doxorubicin as a molecular nanotheranostic agent: effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound-mediated intracellular delivery and nuclear trafficking.Hodgkin's Lymphoma: A Review of Neurologic ComplicationsChemoradionuclide therapy with 186re-labeled liposomal doxorubicin: toxicity, dosimetry, and therapeutic response.A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer.Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapyLocalized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer.Pegylated liposomal doxorubicin in the management of ovarian cancerCancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.Targeted delivery of Doxorubicin by folic acid-decorated dual functional nanocarrierKinetic targeting of pegylated liposomal doxorubicin: a new approach to reduce toxicity during chemotherapy (CARL-trial).Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial.Doxorubicin-conjugated polypeptide nanoparticles inhibit metastasis in two murine models of carcinomaSynthesis and biological characterization of protease-activated prodrugs of doxazolidineBiomarkerless targeting and photothermal cancer cell killing by surface-electrically-charged superparamagnetic Fe3O4 composite nanoparticles.Doxorubicin encapsulated in stealth liposomes conferred with light-triggered drug release.Defined lipid analogues induce transient channels to facilitate drug-membrane traversal and circumvent cancer therapy resistanceNon-pegylated liposomal doxorubicin for patients with recurrent ovarian cancer: A multicentric phase II trialPegylated liposomal doxorubicin in elderly patients with metastatic breast cancer.Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot studyA study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity.Review: doxorubicin delivery systems based on chitosan for cancer therapy.A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity.Targeting Triple Negative Breast Cancer with a Small-sized Paramagnetic Nanoparticle.Polymeric micelles as a new drug carrier system and their required considerations for clinical trials.Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology.Sorafenib-associated hand-foot syndrome in Japanese patients.Docetaxel-associated palmar-plantar erythrodysesthesia: a case report and review of the literature.Actively targeting solid tumours with thermoresponsive drug delivery systems that respond to mild hyperthermia.Application of liposomal technologies for delivery of platinum analogs in oncology.Availability of polymeric nanoparticles for specific enhanced and targeted drug delivery.Therapeutic oligonucleotides with polyethylene glycol modifications.Nanomedicines in gastroenterology and hepatology.Co-nanoencapsulated doxorubicin and Dz13 control osteosarcoma progression in a murine model.Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer.Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters.
P2860
Q24201282-5868E402-A631-4EC0-A950-2B0A2A323D55Q24604735-2FF6D86C-0660-42D9-AE3F-F574D93670A6Q28468353-781FF622-EAC8-4146-B0FB-9CA93B834BE2Q28821119-8885C7D7-E8A0-4D09-B44F-8C69F3627E39Q30250106-DB94D832-D8CB-4905-9950-04F511C08E3EQ30472420-B915F8BA-A95B-4D6F-97B8-57CCFD88EA99Q30479037-F1204491-9A9F-4EDC-BCB9-0BA987000C74Q33396676-2D159294-F723-48A8-8A28-E21E961F7FB6Q33521785-4E6CAC26-276E-4438-B149-358051F4A511Q33802940-2EFAF7DF-F78C-49EE-9FF9-B33A69031911Q34054263-B8970088-5843-425D-A551-A74983153850Q34187661-AD08028B-7E8C-447A-A6A1-7EA6E667B666Q34447986-6C5A727E-6177-4E16-B7A9-908A158764BAQ34473472-DB93F99E-DFCF-474A-8BE8-BCEE279A6605Q35218744-C9A33BF9-E0B7-4A1C-886E-B6604B3F2FD7Q35227792-49B102E1-6D9B-486E-A13F-72A6176C5AC0Q35602635-2402E600-8472-45E7-9150-4BAFA29B8FFDQ36206886-4C8344DC-BC54-472B-B3C7-20D9E4F412DCQ36220325-3DC4EE0F-E49D-4571-A469-40D36340A1DFQ36278952-A7CFE4BF-4222-4027-80EB-AB642AE2B94CQ36907239-681A14A1-612E-4E8F-B60C-8D212E2BA620Q37108705-9DFB6893-976B-4D90-B42C-B0A995456717Q37118928-D8D94D20-D47C-470C-B20C-6B2A5DB9FE11Q37152133-5492108A-F033-4915-8E79-B429C343B3FEQ37322979-5A341FBF-5EBF-4C85-B232-064BDFF55278Q37380142-76733D6A-2FD1-4592-8D4C-126C09BBC721Q37495209-91D2F355-66F4-4323-A874-A0050108A037Q37529757-BD26D706-B3BE-4758-A122-BABB263281EDQ37679942-C22113C9-2269-4ED7-AA50-E33DFC37452FQ37689857-351C57DF-5A62-4D38-8408-5EAC937B1F9EQ37845916-1C66BAC2-1443-4585-BB73-B91EC9A8849FQ38088085-6824C787-D14C-43FE-BEAA-E37DE5AC7E21Q38127266-89574E5F-1616-42C6-9303-C89348937715Q38136184-B603EF62-6208-4B3E-866B-914EC99A26F9Q38151736-F6CF60FD-D340-43D6-90F8-30AEAF570D64Q38296021-2E404E88-30E3-428E-A8DE-C942ED1193AFQ38370747-B9001F2D-9367-44C6-8FB0-966505B00F0CQ39231810-0E98A210-28B7-4969-8DC3-EB6452CD1A62Q40395847-6AEC2FD2-0437-40B1-9FEC-93FC11565389Q40485087-DD61D72B-E9ED-4402-80BB-14155B96A94A
P2860
Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome).
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Pegylated liposomal doxorubici ...... thesia ('hand-foot' syndrome).
@ast
Pegylated liposomal doxorubici ...... thesia ('hand-foot' syndrome).
@en
Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia
@nl
type
label
Pegylated liposomal doxorubici ...... thesia ('hand-foot' syndrome).
@ast
Pegylated liposomal doxorubici ...... thesia ('hand-foot' syndrome).
@en
Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia
@nl
prefLabel
Pegylated liposomal doxorubici ...... thesia ('hand-foot' syndrome).
@ast
Pegylated liposomal doxorubici ...... thesia ('hand-foot' syndrome).
@en
Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia
@nl
P2093
P2860
P356
P1433
P1476
Pegylated liposomal doxorubici ...... thesia ('hand-foot' syndrome).
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDL477
P577
2007-01-17T00:00:00Z